The global cord blood market is reportedly dominated by a small number of large operators, with the 12 largest controlling 70% of the market. There are indications of consolidation in the industry, with major markets seeing a trend towards fewer, larger players. Some of the key players in the market, including FamiCord and CelluGen, are engaging in significant business activities, such as signing letters of intent.